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Clinicopathological analysis of salivary 
gland tumors over a 15-year period 
Abstract: Salivary gland tumors (SGT) are rare neoplasms that generate 
interest due to their histopathological diversity and clinical behavior. 
The aims of the present study were to investigate clinicopathological 
aspects of SGTs diagnosed at a tertiary health center and compare the 
findings with epidemiological data from different geographic locations. 
Cases of tumor in the head and neck region at a single health center in 
the period between 1995 and 2010 were reviewed. Patient gender, age 
and ethnic group as well as anatomic location, histological type and 
clinical behavior of the tumor were recorded. Availability of complete 
information about these aspects was considered the inclusion criteria. 
Descriptive statistical analysis of the data was performed using the 
frequencies of categorical variables. Among the 2168 cases of tumors 
in the head and neck region, 243 (11.20%) cases were diagnosed in 
the salivary glands, 109 of which met the inclusion criteria: 85 (78%) 
benign tumors and 24 (22%) malignant tumors. Mean patient age was 
46.47 years. The female gender accounted for 56 cases (51.4%) and the 
male gender accounted for 53 (48.3%). The major salivary glands were 
affected more (75.2%) than the minor glands. The most frequent benign 
and malignant SGTs were pleomorphic adenoma (81.2%) and adenoid 
cystic carcinoma (58.3%), respectively. In conclusion, pleomorphic 
adenoma and adenoid cystic carcinoma are the most frequent benign 
and malignant lesions, respectively. Comparing the present data with 
previous studies on SGTs, one may infer that some demographic 
characteristics and the predominance of malignant tumors vary in 
different geographic regions.
Keywords: Neoplasms; Salivary Glands; Adenoma, Pleomorphic; 
Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid.
Introduction
Salivary glands tumors (SGTs) are uncommon neoplasms that pose 
a diagnostic challenge due to their complex histopathological features.1 
Moreover, SGTs exhibit considerable variation with regard to clinical 
aspects, biology and clinical behavior.2,3,4
SGTs represent 3 to 6% of all tumors of the head and neck region, 
with an annual incidence throughout the world ranging from 0.05 to 
2 cases per 100,000 individuals.5 Epidemiological data reveal different 
frequencies of SGTs in distinct ethic groups and geographic locations, which 
makes it difficult to establish global estimates.1,6,7,8,9,10,11,12,13,14,15,16 Although 
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studies provide valuable knowledge, some data are 
contradictory. Local records are a useful strategy 
for the analysis of the distribution and particular 
features of SGTs in a specific population and the 
establishment of appropriate treatment.
The aims of present study were to describe 
demographic and clinicopathological aspects of SGTs 
diagnosed at a tertiary health center and compare 
the findings with epidemiological data from different 
geographic locations.
Methodology
A retrospective analysis was carried out using 
archival data from the pathology laboratory of a 
tertiary health center located in southern Brazil 
Hospital de Clínicas de Porto Alegre. This study received 
approval from the Institutional Ethics Committee 
(protocol no. 130152/12).
In a 15-year period spanning from 1995 to 2010, 
2168 cases of tumors in the head and neck region 
were identified, 243 of which were SGTs. Clinical 
data regarding age, gender, clinical aspects, tumor 
localization, TNM Classification, treatment and 
follow-up information (clinical outcome and survival 
time) were retrieved from medical files. The follow-up 
period was defined as the time from diagnosis until 
the last visit to the hospital. Availability of complete 
information about these aspects was considered the 
inclusion criteria and based on these only 109 were 
included. Slides stained with hematoxylin-eosin 
of all cases were reviewed based on the Histologic 
Typing of Salivary Gland Tumors established by the 
World Health Organization (WHO).17 Continuous 
variables were expressed as mean, median and 
standard deviation values. Categorical variables 
were expressed as absolute number of cases and 
percentage values.
Results
Among the 109 cases of SGTs, 81 (74.3%) tumors 
were located in major salivary glands and 28 (25.7%) 
were located in minor salivary glands. The most 
frequent location among the major salivary glands 
was the parotid gland (66.9%), followed by the 
submandibular gland (7.3%). Among the minor 
glands, the most frequent location was the palate 
(14.6%). No cases occurred in the sublingual gland 
(Figure and Table 1).
The male gender accounted for 53 cases (48.3%) 
and the female gender accounted for 56 (51.4%): 
male-to-female ratio of 0.9:1 for benign tumors and 
1:1 for malignant tumors (Table 2). The majority of 
the tumors occurred in patients aged 41 to 60 years 
(median: 45 years). Mean patient age was 46.47 years 
(47.6 years for benign tumors and 42.3 years for 
malignant tumors). Young individuals (0-20 years-old) 
were the second group more affected by malignant 
tumors (25%) (Table 3).
Eighty-five cases (78%) were classified as benign 
tumors and 24 (22%) were malignant tumors 
(benign-to-malignant ratio of 3.5:1). The proportions 
differed depending on the type of salivary gland 
analyzed. Among the 81 cases of SGT in the major 
glands, 67 (82.7%) were benign and 14 (17.3%) were 
malignant. Among the 28 cases in minor salivary 
glands, 18 (64.3%) were benign and 10 (35.7%) were 
malignant (Table 1). Among the 85 benign tumors, 68 
(79.06%) were pleomorphic adenoma and 16 (18.6%) 
were cases of Warthin’s tumor. Among the 24 malignant 
tumors, 14 (58.3%) were adenoid cystic carcinoma, five 
(20.8%) were mucoepidermoid carcinoma and five 
(20.8%) were acinic cell carcinoma (Table 1).
Adenoid cystic carcinoma and mucoepidermoid 
carcinoma were classified based on the WHO 
Histologic Typing of Salivary Gland Tumors.17 
Among the 14 cases of adenoid cystic carcinoma, 
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Figure. Distribution of 109 salivary gland tumors according 
to occurrence in major or minor salivary glands.
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Table 1. Distribution of 109 salivary gland tumors according to anatomic location.
Parotid Submandibular Palate Other
n % n % n % n %
Benign tumors
Pleomorphic adenoma 48 69.6 3 4.3 11 15.9 7 10.1
Warthin’s tumor 16 100.0 0 0.0 0 0.0 0 0.0
Subtotal (% in the group of benign tumors) 64 75.3 3 3.5 11 12.9 7 8.2
Malignant tumors
Adenoid cystic carcinoma 3 21.4 3 21.4 4 28.6 4 28.6
Mucoepidermoid carcinoma 3 60.0 2 40.0 0 0.0 0 0.0
Acinic cell carcinoma 3 60.0 0 0.0 1 20.0 1 20.0
Subtotal (% in the group of malignant tumors) 9 37.5 5 20.8 5 20.8 5 20.8
Total (% according n = 109) 73 66.9 8 7.3 16 14.7 12 11.0
Table 2. Histologic and gender distribution of 109 salivary gland tumors.
n = 109 %
% in the group of benign or 
malignant tumors
Gender
Male Female
n % n %
Benign tumors
Pleomorphic adenoma 69 63.3 81.2 31 28.4 38 34.9
Warthin’s tumor 16 14.7 18.8 10 9.2 6 5.5
Total 85 78 100 41 37.6 44 40.4
Malignant tumors
Adenoid cystic carcinoma 14 12.8 58.3 6 5.5 8 7.3
Mucoepidermoid carcinoma 5 4.6 20.8 3 2.7 2 1.8
Acinic cell carcinoma 5 4.6 20.8 3 2.7 2 1.8
Total 24 22 100 12 10.9 12 10.9
Table 3. Distribution of 109 benign and malignant salivary gland tumors according to age (in years).
0-20 21-40 41-60 > 61
 n  % n % n % n %
Benign tumors
Pleomorphic adenoma 5 7.2 24 34.8 28 40.6 12 17.4
Warthin’s tumor 0 0.0 0 0.0 9 56.3 7 43.8
Subtotal (% in the group of benign tumors) 5 5.9 24 28.2 37 43.5 19 22.4
Malignant tumors
Adenoid cystic carcinoma 1 7.1 2 14.3 8 57.1 3 21.4
Mucoepidermoid carcinoma 2 40.0 0 0.0 2 40.0 1 20.0
Acinic cell carcinoma 3 60.0 2 40.0 0 0.0 0 0.0
Subtotal (% in the group of malignant tumors) 6 25.0 4 16.7 10 41.7 4 16.7
Total (% according n = 109) 11 10.1 28 25.7 47 43.1 23 21.1
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seven (50.0%) cases were cribriform, five (35.7%) 
were tubular and two (14.3%) were solid. Among 
the five cases of mucoepidermoid carcinoma, four 
were classified as low-grade and one was classified 
as intermediate-grade.
Regarding the clinical aspects, all benign tumors 
were nodules, whereas malignant tumors were nodules 
in 19 cases (11 cases of adenoid cystic carcinoma, four 
cases of mucoepidermoid carcinoma and four cases 
of acinic cell carcinoma) and ulcerated nodules in 
five cases (three cases of adenoid cystic carcinoma, 
one case of mucoepidermoid carcinoma and one case 
of acinic cell carcinoma). Among the 24 malignant 
tumors, 11 (45.8%) cases were classified as TNM 
stage I or II and 13 (54.2%) cases were classified as 
stage III or IV.
All patients underwent surgical treatment. 
Thirteen patients (11.92%) with malignant tumors also 
underwent radiation therapy. Among these patients, 
seven (53.8%) cases were adenoid cystic carcinoma, 
three (23.1%) were mucoepidermoid carcinoma and 
three (23.1%) were acinic cell carcinoma. The follow-up 
period ranged from four to 17 years (mean: 7.4 years). 
During the follow-up period, 19 patients (79.2%) of 
malignant lesions remained alive without recurrence 
and only one (4.2%) remained alive but with recurrence 
(adenoid cystic carcinoma). One patient (4.2%) died 
due to an unspecified cause and three (12.6%) died 
due to the tumor (TNM stages III and IV): one case 
(4.2%) of acinic cell carcinoma and two cases (8.4%) of 
adenoid cystic carcinoma. Recurrence was observed 
in four cases (3.66%) of pleomorphic adenoma and 
four cases (3.66%) of adenoid cystic carcinoma.
Discussion
A morphologically diverse group of rare tumors 
arises from salivary glands. These tumors have different 
biological behaviors and their etiopathogenesis 
remains unknown.2,5 Epidemiologic studies conducted 
in different parts of the world report differences in 
the incidence as well as frequency of histological 
types of SGTs (Table 4). The present study reviewed 
the demographic and clinicopathologic aspects of 109 
cases of SGTs diagnosed at a tertiary health center 
and the findings are in general agreement with data 
reported in previous studies.1,8,10,12,15,16,18
According to the literature, the most common 
clinical presentation of SGT is a well-circumscribed 
nodular tumor with a normal overlying surface 
color. SGTs are usually asymptomatic and affect 
females more, with peak incidence occurring the fifth 
and seventh decades of life.10,15,17,19,20,21,22 The clinical 
features that allow the differentiation of benign and 
malignant SGTs are the evolutionary course, pain 
and ulceration. Benign tumors tend to be insidious 
and slow growing, with an average course of three 
to six years and no adherence to surrounding tissues. 
Malignant lesions exhibit fast growth (often less than 
one year of evolution) and adhere to deep layers, with 
an ulcerated or telangiectatic surface. Pain is the 
most suggestive characteristic of malignancy.17 In the 
present series, the majority of clinical characteristics 
observed were similar to those reported in previous 
studies. Patient age ranged from nine to 81 years 
old, with a mean of 46.47 years. The tumors were all 
nodules and 4.6% were ulcerated. The only difference 
in comparison to previous reports was the similar 
male-to-female ratio (0.94:1) with both benign and 
malignant tumors. Although uncommon, Lukšić et al.15 
and Tian et al.16 report similar findings.
Major salivary glands were affected more than 
minor glands, especially the parotid gland (66.9%), 
followed by palatine glands (14.7%). Similar results 
are described in the majority of studies on SGTs 
(Table 4), including those from Brazil (Table 5).1,6,7 
The predominance of SGTs in major salivary glands 
may be explained by the fact that the present study 
was conducted at tertiary health center that receives 
most patients with parotid tumors. SGTs in minor 
salivary glands are usually diagnosed and treated 
at primary and secondary services, whereas only 
malignant SGTs in major salivary glands are referred 
to the hospital service.
Benign SGTs predominated in the major glands 
and comprised 78% of all salivary tumors, which is 
similar to rates reported in studies conducted in Iran,19 
Congo,18 the United Kingdom,23 Jordan,24 Brazil6,7 and 
China,16 in which benign tumors accounted for more 
than 50% of all salivary tumors, suggesting that such 
tumors are the predominant form of SGTs worldwide. 
In the present study, the benign-to-malignant ratio 
was 3.5:1. Few studies report a greater prevalence 
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of malignant SGTs.11 In such cases, the uncommon 
findings may be explained by the fact that the studies 
were conducted at tertiary centers, which receive 
more severe cases of SGTs.
Pleomorphic adenoma is a benign neoplasm 
composed of epithelial and myoepithelial cells 
arranged in a large variety of morphological patterns, 
with areas of mesenchymal differentiation. In the 
present series, this tumor was the most frequent type 
of SGT, accounting for 63.3% of all tumors and 81.2% 
of benign tumors. The majority of such cases (73.9%) 
were located in major salivary glands. The frequency 
of pleomorphic adenoma ranges from 40.9% to 73.8% 
of all STGs (Table 4).11,21 Studies involving large series 
of SGTs report similar results, with pleomorphic 
adenoma representing 60% to 73% of parotid gland 
tumors as well as 40% to 60% of submandibular 
and minor salivary gland tumors.11,21 All cases of 
pleomorphic adenoma reported in the present study 
were treated by surgery and recurrence was observed 
in four cases (3.66%).
Adenoid cystic carcinoma was the most prevalent 
malignant SGT (14 cases), representing 12.8% of all 
tumors and 58.3% of malignant tumors, followed 
by mucoepidermoid carcinoma and acinic cell 
carcinoma. The predominance of adenoid cystic 
carcinoma has been described in studies conducted 
in Congo, Tanzania, Croatia and Nigeria. In contrast, 
studies conducted in Iran, Brazil, Jordan, the USA, the 
United Kingdom and Italy report a greater frequency 
of mucoepidermoid carcinoma than adenoid cystic 
carcinoma, whereas similar distribution between 
these two types of SGTs has been reported in 
China, Finland and Mexico (Table 4). These findings 
Table 4. Distribution of salivary gland tumors in different countries.
Region Authors
Number of cases Benign Malignant Major Minor PA CAC MEC
(n) (% of all tumors)
China Tian et al. 2010 6982 67.9 32.1 71.6 28.4 47 9.7 9.6
China Li et al. 2008 3461 59.8 40.2 73.6 26.4 51.3 7.3 7.5
USA Spiro et al. 1986 2807 54.5 45.5 78 22 45.4 10 15.7
Finland and Israel Bello et al. 2012 1888 85.1 14.9 90 10 50 3.5 3.2
Croatia Luksic et al. 2011 779 64.2 35.8 72.8 27.2 47.2 11.7 8.2
UK Jones et al. 2008 741 64.9 35.1 38.6 61.4 44.4 8.4 11.5
Brazil de Oliveira et al. 2009 599 78.3 21.7 78.3 21.7 67.8 6.5 4.8
Brazil Ito et al. 2009 496 67.5 32.5 77.2 22.8 54.2 7.9 13.5
Brazil Fonseca et al. 2012 493 50.5 49.1 74.8 25.1 85 17.7 31.4
Italy Ascani et al. 2006 454 89.2 10.3 93.4 6.6 63.2 1.8 3.3
Nigeria Lawal et al. 2013 413 46.5 53.5 55 45 40.9 22.5 14.8
Mexico Meija-Velazquez et al. 2012 360 67 23 76.4 23.6 65.6 5 4.7
Israel Bello et al. 2012 330 66.4 33.7 66.7 33.3 70.5 31.8 28.2
Congo Kayeme et al. 2002 275 65.5 34.5 61.5 38.5 55.3 16 8
Uganda Vuhahula 2004 268 32.8 67.2 54.1 45.9 73.8 29.3 20.3
Jordan Ma’aita et al. 1999 221 68.3 31.7 81 19 62.9 5.4 17.2
Tanzania Masanja et al. 2003 133 54 46  42.4 57.6 44.4 24.8 9.8
Iran Ansari et al. 2007 130 68.5 31.5 86.1 13.9 65.4 2.3 11.5
Brazil Present study 109 78 22 74.3 25.7 63.3 12.8 4.6
Nigeria Otoh et al. 2005 79 55.7 44.3 58.2 41.8 44.3 8.9 10.1
Table 5. Reports of salivary gland tumors in different states 
and regions in Brazil.
State/Region Authors
Number of cases
 (n)
Goiás/Middle-West de Oliveira et al. 2009  599
Paraná/South Ito et al. 2009  496
Paraná/South –
São Paulo/Southeast
Fonseca et al. 2012  493
Rio Grande do Sul/South Present study  109
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suggest geographic variation in the frequency of 
malignant SGTs.
Adenoid cystic carcinoma exhibited the worst 
behavior among all SGTs analyzed. This tumor 
has a slow growth pattern with the early nerve and 
lymph node involvement. Advanced tumors require 
surgery and radiation therapy.25 In the present study, 
adenoid cystic carcinoma recurred in four cases 
(28.6%) and death occurred in an additional two 
cases (14.28%). The patients in these cases were in 
TNM stages III or IV and received surgery plus 
radiation therapy. According to previous studies, 
the majority of patients with distant metastasis of 
an adenoid cystic carcinoma have tumor size of T3 
or T4 and that surgery and radiation therapy achieve 
excellent results regarding both local and regional 
control.5,26,27 Another important aspect is the presence 
of perineural invasion, which is a common finding in 
adenoid cystic carcinoma that appears to contribute 
to a worse outcome.27 The mean follow-up period in 
the present study was 7.4 years and a high survival 
was observed. However, previous studies indicate 
that survival rates are usually high in the first five 
years, whereas the cure rate over a 20-year period is 
much lower.5,8,26,27
Conclusion
In this retrospective study, major salivary glands 
were more affected than minor glands by neoplastic 
processes and pleomorphic adenoma and adenoid 
cystic carcinoma were the most frequent benign and 
malignant tumors, respectively, at a tertiary health 
center in southern Brazil. Analyzing the present 
findings in light of data from previous studies on SGTs, 
one may infer that some demographic characteristics 
(e.g., gender and age) and the predominance of 
malignant tumors (e.g., adenoid cystic carcinoma 
and mucoepidermoid carcinoma) vary in different 
geographic regions. Factors that influence SGT 
behavior and prognosis should be investigated further.
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